New diabetes clinical trial: To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Type 2 Diabetes.

Published on: November 07, 2019 at 10:30PM
Conditions:   Dyslipidemia;   Type 2 Diabetes
Interventions:   Drug: AZD8233 subcutaneous injection;   Drug: Placebo
Sponsors:   AstraZeneca;   Parexel
Not yet recruiting
https://ift.tt/36KNdsL